A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine Subdermal Implants

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine Subdermal Implants

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine (Primary)
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Sponsors Braeburn Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2016 Data from this trial presented at the International Society of Addiction Medicine (ISAM) annual meeting, as per Braeburn Pharmaceuticals media release.
    • 19 Jul 2016 Results published in the JAMA: the Journal of the American Medical Association (2016).
    • 16 Jun 2016 Results published in a Braeburn Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top